CytomX Therapeutics Unveils Promising Phase 1 CX-801 Data in Advanced Melanoma at SITC 2025
Reuters
Nov 04, 2025
<a href="https://laohu8.com/S/CTMX">CytomX</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Promising Phase 1 CX-801 Data in Advanced Melanoma at SITC 2025
CytomX Therapeutics Inc. announced that initial translational data from the ongoing Phase 1 study of CX-801, a masked interferon alpha-2b PROBODY® cytokine, in patients with advanced melanoma will be presented at the Society for Immunotherapy of Cancer $(SITC)$ 40th Anniversary Annual Meeting, scheduled for November 7-9, 2025. According to the company, early results indicate that CX-801 is generally well tolerated and demonstrates activation of tumor-selective interferon signaling in patients with advanced melanoma, including those refractory to prior immune checkpoint inhibitor therapy. These findings support the rationale for an ongoing Phase 1 combination study of CX-801 with KEYTRUDA® (pembrolizumab). The company plans to present Phase 1 clinical data of the CX-801 and KEYTRUDA® combination in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565261-en) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.